FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Breakthrough for Central Venous Oxygenation Monitor

[ Price : $8.95]

FDA grants Noninvasix a breakthrough device designation for its LivOx Central Venous Oxygenation Monitor for monitoring central ve...

Meeting on Biosimilar User Fee Program Assessment

[ Price : $8.95]

Federal Register notice: FDA announces a 3/22 virtual public meeting on the biosimilar user fee programs enhanced review transpare...

OPDP Social Science Research Explained

[ Price : $8.95]

CDER Office of Prescription Drug Promotion senior social science research analyst Katherine Aikin explains the work her unit does ...

CDER Office of Pharmaceutical Quality Report

[ Price : $8.95]

The CDER Office of Pharmaceutical Quality reports on its 2021 core function activities and efforts to carry out White House recomm...

Guidance on Primate Supply for Drug Nonclinical Use

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Nonclinical Considerations for Mitigating Nonhuman Primate ...

AdvaMed on Device EUA Transition Plan

[ Price : $8.95]

AdvaMed comments on an FDA proposed information collection to prepare transition plans for some medical devices after the Covid-19...

Mallinckrodt Complete Response on Terlipressin NDA

[ Price : $8.95]

FDA issues a second complete response letter in less than 18 months to Mallinckrodt for its NDA for terlipressin to treat adults w...

28-Page FDA-483 for Edge Pharma Inspection

[ Price : $8.95]

FDA releases a lengthy FDA-483 with 13 observations from a two-month inspection at Colchester, VT-based Edge Pharma drug outsourci...

Sanofi/GSK to Submit Covid Vaccine Data

[ Price : $8.95]

Sanofi and GlaxoSmithKline say a Phase 3 trial of their Covid-19 vaccine showed it was 100% effective against severe Covid disease...

AbbVie Seeks Vraylar OK for Major Depression

[ Price : $8.95]

AbbVie files a supplemental NDA for Vraylar (cariprazine) for the adjunctive treatment of major depressive disorder in patients wh...